Ramucirumab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | VEGFR2 (KDR) |
| Identifiers | |
| CAS Number | 947687-13-0 |
| ATC code | none |
| Chemical data | |
| Formula | C6374H9864N1692O1996S46 |
| Molar mass | 143.6 kDa[[Script error: No such module "String".]] |
Ramucirumab (IMC-1121B) is a monoclonal antibody used in the treatment of solid tumors.
Ramucirumab is a fully-human monoclonal antibody directed against VEGFR2. It blocks the binding of vascular endothelial growth factor (VEGF) to its receptor (VEGFR2) and thereby acts as an inhibitor of angiogenesis in the treatment of cancer. In early 2009, the antibody was in a phase III clinical trial for breast cancer, with phase III trials in other solid tumor indications expected to commence shortly. [1]
This drug was developed by ImClone Systems Inc. It was isolated from a Dyax native phage display library.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ramucirumab, American Medical Association.
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
